Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Linerixibat in Moderate Hepatic Impairment
NCT05393076Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of linerixibat in pruritus and primary biliary cholangitis (PBC) (2 arms), sponsored by GSK. Primary endpoints: Plasma area under the concentration-time curve from time zero to the time of the last quantifiable concentration and Maximum observed concentration. Started Jul 2022; status: completed.
02
Drugs
linerixibat
03
Conditions
pruritusprimary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT05393076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393076.